Medical Science Liaison - Nationwide

Company Overview

Pancreatic cancer remains one of the deadliest solid tumors, in part because tumors resist drug uptake from systemic chemotherapy while patients absorb its full toxicity. RenovoRx, Inc. (Nasdaq: RNXT), headquartered in Mountain View, California, addresses that problem with its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which delivers therapeutic agents across the arterial wall directly at the tumor site. The platform is enabled by RenovoCath®, an FDA-cleared drug-delivery device that entered commercial use in December 2024 and was active at 21 U.S. cancer centers by mid-2026, including City of Hope and Moffitt Cancer Center. RenovoRx's lead drug-device combination candidate, intra-arterial gemcitabine (IAG), completed enrollment in the Phase III TIGeR-PaC trial in locally advanced pancreatic cancer in August 2026 and holds FDA Orphan Drug Designation for pancreatic and bile duct cancer. The company's field sales team works primarily with interventional radiologists; the Medical Science Liaison is RenovoRx's first, extending its scientific reach to the medical, surgical, and radiation oncologists who drive referral and treatment decisions.

Job Overview

As a Medical Science Liaison (MSL), you will serve as a scientific and clinical expert, building trusted relationships with healthcare professionals (HCPs), mostly medical, surgical, and radiation oncologists, to develop these physicians and their staff into TAMP experts across academic and community settings locally, regionally, and nationally. You will bridge scientific evidence and clinical practice, deliver impactful medical education, and generate actionable field insights. You will report to the Chief Medical Officer (CMO) and partner with the management team.

As the company's first MSL, you will do more than answer questions in meetings others have arranged. RenovoRx is looking for someone who will proactively identify and gain access to key oncology decision-makers at high-volume cancer centers, engage them peer-to-peer on Phase III oncology data relative to the standard of care, and challenge assumptions with evidence. This is a scientific role with an entrepreneurial, door-opening mindset, working closely alongside the sales team.

This is a high-visibility, cross-functional role suited to an entrepreneurial, intellectual, and detail-oriented individual who thrives in a dynamic environment and is motivated by the impact of their work on patient outcomes. As the medical affairs field function grows, this role offers the opportunity to help build and lead it.

Products

• TAMP™ therapy platform: Designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
• RenovoCath®: Patented, FDA-cleared dual-occlusion drug-delivery catheter indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. In commercial use since December 2024, with first commercial use beyond pancreatic cancer in sarcoma.
• IAG (intra-arterial gemcitabine via RenovoCath): Investigational drug-device combination evaluated by the FDA's Center for Drug Evaluation and Research under a U.S. IND (21 CFR 312). The Phase III TIGeR-PaC trial in locally advanced pancreatic cancer requires 114 randomized patients; enrollment closed in August 2026, with trial completion expected in 2027.
• Interim Phase III data: The first interim analysis of TIGeR-PaC showed a 6-month median overall survival trend and an 8-month median progression-free survival difference (15 vs. 7 months) versus IV gemcitabine and nab-paclitaxel, along with a greater than 65% reduction in adverse events.
• PK/PD evidence: A peer-reviewed TIGeR-PaC sub-study reported approximately 51% tumor-site drug extraction and decreased systemic exposure with TAMP delivery.
• Orphan Drug Designations: Gemcitabine delivered via RenovoCath for pancreatic and bile duct cancer, and oxaliplatin for pancreatic cancer, each carrying seven years of market exclusivity upon FDA approval.

Qualifications

Education & Experience

• Master's degree in life science or related field required
• Advanced degree (PhD, PharmD, or MD) strongly preferred; an MD (U.S. or internationally trained) or PhD in pharmacology is especially valued
• Minimum 5 years as a Medical Science Liaison, ideally within GI medical oncology supporting liquid biopsies, drug-device combinations, or drug delivery systems
• Demonstrated ability to conduct medical education programs and build strong partnerships with community and academic centers
• Deep understanding of NCCN and ASCO guidelines, oncology treatment paradigms, and emerging therapeutic technologies
• Skilled in presenting scientific data, developing abstracts/manuscripts, and contributing to publication planning

Preferred

• Oncology MSL experience with a small or niche pharmaceutical or biotech company; candidates whose careers include large pharma should also bring experience in smaller organizations
• Pharmaceutical oncology background preferred over device MSL experience; drug-device combination experience is welcome
• Liquid biopsy / ctDNA oncology market experience
• Experience generating medical oncology referrals into interventional or locoregional therapies
• Established relationships with medical oncologists, particularly in pancreatic and GI cancers

Competencies

• Excellent communication and relationship-building skills; extroverted and collaborative
• Confident engaging physicians head-to-head - able to compare Phase III oncology data against the standard of care and challenge assumptions with evidence
• Proactive and resourceful in identifying and securing access to KOLs and decision-makers without relying solely on sales-generated introductions
• Strong analytical and organizational capabilities with attention to detail
• Strong ability to engage with KOLs, clinicians, and investigators across oncology subspecialties
• Self-starter comfortable working independently in a field-based role at a small company without a large support structure
• Able to fluently discuss oncology topics, including patient subtyping and emerging therapeutic modalities (e.g., KRAS inhibitors, ctDNA, CA19-9, oncolytic viruses, TILs, CAR-T)
• Proficiency in CRM and digital engagement tools (e.g., Asana, Salesforce)
• Commitment to ethical conduct and compliance with all regulatory standards

Credentialing & Travel

• Must meet all vendor credentialing requirements necessary to gain client site access, unless prohibited by law; requirements vary by site and may include valid identification, criminal background check, drug screens, immunizations (Hep B, MMR, Varicella, Influenza, Tetanus), annual TB testing, and healthcare trainings
• Significant travel required - approximately 14 days per month to clinical sites, conferences, and internal meetings

Job Responsibilities:

Scientific Engagement & Education

• Develop and maintain credible, peer-to-peer scientific relationships with physician KOLs in medical oncology, surgical oncology, and radiation oncology
• Conduct evidence-based discussions and deliver scientific presentations to clinicians, ensuring communication remains non-promotional and compliant
• Engage oncologists on Phase III oncology data in the context of the current standard of care
• Host and co-develop educational programs, including peer-to-peer webinars, dinner meetings, and local workshops with Sales and Marketing
• Provide in-depth, center-specific training (e.g., patient selection criteria and adverse event mitigation)
• Teach internal and external training courses as a subject matter expert on treatments utilizing RenovoCath technology

KOL Access & Center Development

• Proactively identify and secure meetings with medical oncology KOLs and decision-makers at high-volume target cancer centers
• Build access to medical oncologists, practices, and tumor boards beyond the reach of the interventional radiology-focused sales team
• Partner with Sales to support the opening of new academic and community cancer centers

Clinical Insights & Field Intelligence

• Regularly engage centers (virtual and in-person) to identify trends, barriers, and opportunities in care delivery
• Gather and synthesize field insights to inform Medical Affairs, Clinical Development, and Communications strategies
• Submit monthly reports highlighting clinical trends, physician feedback, and competitive intelligence
• Utilize CRM systems to track field activity, interactions, and KOL engagement

Congress & Conference Participation

• Represent RenovoRx at key scientific meetings, symposia, congresses, and hosted events
• Attend sessions to stay current on new data, engage with investigators, and communicate relevant findings internally
• Support KOL speakers and ensure accurate, timely scientific communication from the field

Cross-Functional Collaboration

• Partner with Sales, Marketing, and Clinical Research to ensure scientific alignment and strategic consistency across messaging, educational initiatives, and business strategy
• Collaborate closely with R&D, Regulatory, and Clinical teams to integrate field insights into development and evidence generation plans
• Contribute to publication planning, data dissemination, and thought leader engagement strategies
• Act as a bridge between external clinicians and internal leadership by identifying unmet needs, spotting opportunities, and translating insights into actionable strategies

Compensation

• Base: commensurate with experience
• Annual bonus opportunity and stock options
• Medical, dental, and vision; 401(k) with match; cell phone stipend; monthly lifestyle benefit reimbursement; paid holidays, vacation, and sick time

Location

• Candidate Location: Remote, Anywhere in the U.S. near a major airport